1. Home
  2. UCAR vs DCOY Comparison

UCAR vs DCOY Comparison

Compare UCAR & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.37

Market Cap

3.1M

ML Signal

HOLD

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$4.64

Market Cap

2.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UCAR
DCOY
Founded
2013
N/A
Country
China
United States
Employees
N/A
11
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
2.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
UCAR
DCOY
Price
$1.37
$4.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$50.00
$30.00
AVG Volume (30 Days)
5.0M
7.8K
Earning Date
05-15-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.53
52 Week High
$4.98
$9.09

Technical Indicators

Market Signals
Indicator
UCAR
DCOY
Relative Strength Index (RSI) 48.03 34.80
Support Level $1.14 $0.61
Resistance Level $1.71 $6.24
Average True Range (ATR) 0.19 0.45
MACD -0.07 -0.15
Stochastic Oscillator 11.65 16.66

Price Performance

Historical Comparison
UCAR
DCOY

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Share on Social Networks: